Treatment with doxorubicin
and/or guggulsterone resulted in no significant differences in body weight, and caused no death.
A team led by scientists at The University of Texas MD Anderson Cancer Center has identified an unexpected mechanism that drives the drug's attack on heart muscle, providing a new approach for identifying patients who can safely tolerate doxorubicin
and for developing new drugs.
A recent phase II trial randomized 96 patients with metastatic or unresectable HCC to receive oral sorafenib (400 mg twice daily) plus doxorubicin
(60 mg/ m2 every 21 days, for a maximum total dose of 360 mg/m2) or placebos plus the doxorubicin
Concomitant administration of resveratrol with doxorubicin
has recently been suggested as a novel strategy to protect against the cardiotoxicity doxorubicin
of and was demonstrated to increase the viability of cardiac myocytes in vitro (13, 14).
It is approved for reducing the incidence and severity of doxorubicin
-associated cardiomyopathy in women with metastatic breast cancer who have received a cumulative doxorubicin
dose of 300 mg/[m.
Dilated cardiomyopathy, which is the most serious complication, usually presents at least one year after doxorubicin
the median survival in the arm of doxorubicin
plus tesmilifene was 23.
DTS-201 consists of doxorubicin
(a marketed cytotoxic compound used in treating several cancer types) conjugated to a proprietary peptide technology discovered in 1996 by Pr.
Treatment of a large high-grade neurofibrosarcoma with concomitant vinblastine, doxorubicin
, and radiotherapy.
kills tumor cells but also can cause heart damage.
hydrochloride (Adriamycin) and daunorubicin hydrochloride (Cerubidine) are 2 such drugs, which compose a larger class known as anthracyclines.
The patient received three cycles of doxorubicin
, but the authors did not state the dosages (1).
LOS ANGELES -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced that an in vivo trial investigating aldoxorubicin, its tumor-targeting conjugate of the widely used chemotherapeutic agent doxorubicin
, in combination with unconjugated doxorubicin
, demonstrated positive results and provided the basis for the Company's current evaluation of the combination therapy in cancer patients with advanced solid tumors in a Phase 1b clinical trial.
equivalents), administered intravenously every 4 weeks.
today announced that its lead oncology compound, zoptarelin doxorubicin
(formerly AEZS 108), met the primary end-point of the investigator-driven and sponsored Phase 2 clinical trial in Castration and taxane Resistant Prostate Cancer (CRPC) and demonstrated good tolerability.